March 25, 2025- MediLink Therapeutics (“MediLink”), a clinical-stage biotechnology company, announces the presentation of preclinical data for two innovative ADC programs (YL217, a CDH17-targeting ADC, and YL242, a VEGF-targeting ADC) and its next-generation dual payload platform at the upcoming AACR Annual Meeting 2025. AACR will be held in Chicago, US April 25-30. Information for the presented studies are as follows:
Poster 1：
Title: Preclinical development of a next generation antibody drug conjugate (ADC) targeting CDH17 for treatment of solid tumors
Session Start: 4/28/2025 2:00:00 PM Session End: 4/28/2025 5:00:00 PM Location: Poster Section 17
Poster 2：
Title: Preclinical development of YL242, a non-internalized antibody-drug conjugate (ADC) targeting soluble VEGF for treatment of solid tumors
Session Start: 4/28/2025 2:00:00 PM Session End: 4/28/2025 5:00:00 PM Location: Poster Section 24
Poster 3：
Title: An innovative dual-payload ADC combining topoisomerase 1 inhibitor and a tubulin inhibitor efficiently overcomes drug resistance
Session Start: 4/28/2025 9:00:00 AM Session End: 4/28/2025 12:00:00 PM Location: Poster Section 23
About MediLink
MediLink Therapeutics, founded in 2020, is a clinical stage biotech company dedicated to developing innovative conjugated drugs for global patients. MediLink has developed a variety of innovative and proprietary linker-payload systems with different mechanisms of action. Among them, the established tumor microenvironment-activatable toxin-linker platform (TMALIN®) technology platform currently has enabled 10 ADC candidates entering clinical stage in the US and China. The goal of the company is to provide better treatment options for global patients and address unmet medical needs. The company is located in Suzhou and Boston, with subsidiaries in Shanghai and Singapore.
About YL217
YL217 is an antibody-drug-conjugate that targets Cadherin-17 (CDH17), a glycoprotein primarily expressed on tumors of the gastrointestinal tract. Specifically, CDH17 is most commonly expressed in gastric cancer, colorectal cancer, pancreatic cancer, and hepatocellular carcinoma. In these malignancies, high expression of CDH17 is often associated with metastatic progression, and is upregulated in late-stage, highly-differentiated tumors. YL217 has been developed by utilizing MediLink's Tumor Microenvironment Activable LINker-payload (TMALIN®) technology platform. The phase I trial for YL217 has been initiated.
About YL242
YL242 is an antibody-drug-conjugate that targets Vascular Endothelial Growth Factor (VEGF). VEGF plays an important role in tumor angiogenesis within the tumor microenvironment. Although VEGF is a well-validated anti-tumor target, limitations in traditional ADC traditional technology has hindered development of a VEGF-targeted ADC. For many tumor types, increased VEGF expression is correlated with disease progression. YL242 has been developed by utilizing MediLink's Tumor Microenvironment Activable LINker-payload (TMALIN®) technology platform. The phase I trial for YL242 is in preparation.
